Show Summary Details
It is sometimes desirable to compare a less expensive treatment or intervention against a treatment or intervention that is already known to be effective. In these cases, it would be unethical to expose participants to an inactive placebo. Thus, these trial designs assess whether the treatment or intervention under study (the “new intervention”) is no worse than an existing alternative (the “active control”). In equivalence and noninferiority trials, authors must prespecify a margin of noninferiority (Δ), within which the new intervention can be assumed to be no worse than the active control. There are a number of methods for arriving
Equivalence and Noninferiority Trials
Equivalence and Noninferiority Trials
Access to the complete content on AMA Manual of Style requires a subscription or purchase. Public users are able to search the site without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
